AIM: To characterize cytochrome P4501A1 (CYP1A1), glutathione S-transferases (GSTs) and microsomal epoxide hydrolase (mEH) polymorphisms in Chinese esophageal cancer patients. METHODS: Multiplex polymerase chain reaction (PCR) and PCR based restriction fragment length polymorphisms (PCR-RFLP) were used to detect polymorphism changes of CYP, GSTs and mEH on esophageal cancerous and precancerous lesions as well as in case control group. All the examination samples were obtained from Linzhou (formerly Linxian), Henan Province, the highest incidence area for esophageal cancer. RESULTS: The frequency of CYP1A1 3' polymorphism in case control group (26/38, 68 %) was significantly higher than in esophageal squamous cell carcinoma group (ESCC) (29/62, 47 %) (P<0.05). A significant difference in the incidence of mEH slow allele variant was observed between case control group (15/38, 39 %) and esophageal dysplasia group (22/32, 69 %) or ESCC group (39/62, 63 %) (P<0.05). However, no significant difference was observed among different groups in the polymorphisms of CYP1A1 exon 7, GSTM1, GSTT1, GSTP1 and mEH fast allele. CONCLUSION: The present results suggest that CYP1A1 3' polymorphism may be one of the promising protective factors and its wild gene type may be an indicator for higher susceptibility to esophageal cancer. mEH slow allele variant, associated with the progression of esophageal precancerous lesions, may contribute to the high susceptibility to esophageal carcinoma.
AIM: To characterize cytochrome P4501A1 (CYP1A1), glutathione S-transferases (GSTs) and microsomal epoxide hydrolase (mEH) polymorphisms in Chinese esophageal cancerpatients. METHODS: Multiplex polymerase chain reaction (PCR) and PCR based restriction fragment length polymorphisms (PCR-RFLP) were used to detect polymorphism changes of CYP, GSTs and mEH on esophageal cancerous and precancerous lesions as well as in case control group. All the examination samples were obtained from Linzhou (formerly Linxian), Henan Province, the highest incidence area for esophageal cancer. RESULTS: The frequency of CYP1A1 3' polymorphism in case control group (26/38, 68 %) was significantly higher than in esophageal squamous cell carcinoma group (ESCC) (29/62, 47 %) (P<0.05). A significant difference in the incidence of mEH slow allele variant was observed between case control group (15/38, 39 %) and esophageal dysplasia group (22/32, 69 %) or ESCC group (39/62, 63 %) (P<0.05). However, no significant difference was observed among different groups in the polymorphisms of CYP1A1 exon 7, GSTM1, GSTT1, GSTP1 and mEH fast allele. CONCLUSION: The present results suggest that CYP1A1 3' polymorphism may be one of the promising protective factors and its wild gene type may be an indicator for higher susceptibility to esophageal cancer. mEH slow allele variant, associated with the progression of esophageal precancerous lesions, may contribute to the high susceptibility to esophageal carcinoma.
Authors: M Deakin; J Elder; C Hendrickse; D Peckham; D Baldwin; C Pantin; N Wild; P Leopard; D A Bell; P Jones; H Duncan; K Brannigan; J Alldersea; A A Fryer; R C Strange Journal: Carcinogenesis Date: 1996-04 Impact factor: 4.944
Authors: T Nakajima; R S Wang; Y Nimura; Y M Pin; M He; H Vainio; N Murayama; T Aoyama; F Iida Journal: Carcinogenesis Date: 1996-07 Impact factor: 4.944
Authors: J M Lancaster; H A Brownlee; D A Bell; P A Futreal; J R Marks; A Berchuck; R W Wiseman; J A Taylor Journal: Mol Carcinog Date: 1996-11 Impact factor: 4.784
Authors: Li Dong Wang; Qi Zhou; Chang Wei Feng; Bin Liu; Yi Jun Qi; Yan Run Zhang; Shan Shan Gao; Zong Min Fan; Yun Zhou; Chang S Yang; Jun Ping Wei; Shu Zheng Journal: Gan To Kagaku Ryoho Date: 2002-02
Authors: Gülnaz Korytina; Olga Kochetova; Leysan Akhmadishina; Elena Viktorova; Tatyana Victorova Journal: Balkan Med J Date: 2012-09-01 Impact factor: 2.021